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Abstract 21 
Background: Pathologic features of end stage pulmonary sarcoidosis (ESPS) are not well 22 
defined; anecdotal reports have suggested that ESPS may mimic usual interstitial pneumonia 23 
(UIP). We hypothesized that ESPS has distinct histologic features. 24 
Methods: Twelve patients who had a diagnosis of pulmonary sarcoidosis and underwent lung 25 
transplantation were included. Controls were 10 age and sex matched lung transplant patients 26 
with UIP. H&E-stained sections were examined for the following features: extent/pattern of 27 
fibrosis; presence/quantity (per 10 high power fields) of fibroblast foci and granulomas; 28 
distribution and morphology of granulomas; presence/extent of honeycomb change. Extent of 29 
fibrosis and honeycomb change was scored as follows: 1=1-25%; 2=26-50%; 3=51-75%; 4=76-30 
100% of lung parenchyma. 31 
Results: Eight of 12 cases demonstrated histological findings typical of ESPS. All showed well-32 
formed granulomas with associated fibrosis distributed in a distinct lymphangitic fashion.  33 
Granulomas were present in hilar or mediastinal lymph nodes from 6 of 6 ESPS cases and none 34 
of 8 control cases. The extent of fibrosis, honeycomb change, and fibroblast foci was 35 
significantly lower in ESPS cases compared to control cases. Two patients with remote histories 36 
of sarcoidosis showed histologic features of diseases other than ESPS (UIP and emphysema) 37 
without granulomas. Two patients with atypical clinical findings demonstrated non-necrotizing 38 
granulomas combined with either severe chronic venous hypertension or UIP.  39 
Conclusions: ESPS and UIP have distinct histopathologic features in the lungs. Patients with a 40 
pre-transplant diagnosis of sarcoidosis may develop other lung diseases that account for their end 41 
stage fibrosis.  42 
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Introduction 43 
Sarcoidosis is a disease of unknown etiology characterized by granuloma formation involving 44 
multiple organ sites1. The lungs are the most commonly involved organ; approximately 95% of 45 
sarcoidosis patients have computed tomographic (CT) evidence of lung disease 2,3. The diagnosis 46 
depends on a combination of clinicoradiological features, non-necrotizing granulomas in a tissue 47 
biopsy, and exclusion of other etiologies, especially granulomatous infection 4. Most cases 48 
involving the lungs follow a benign course and either resolve spontaneously or respond to steroid 49 
treatment; 10 to 30% of patients experience progressive fibrosis resulting in respiratory failure 5-50 
9. 51 
Little is known about the pathologic features of end stage pulmonary sarcoidosis (ESPS). 52 
Pathologic features of ESPS have been described in three studies of 17 patients in the English 53 
literature. H. Shigemitsu et al10 described 7 patients with ESPS who underwent lung 54 
transplantation. Only four of the explanted lungs showed granulomas characteristic of ESPS; two 55 
displayed patchy interstitial fibrosis and fibroblast foci consistent with usual interstitial 56 
pneumonia (UIP). Aisner and Albin11 reported a case of advanced pulmonary sarcoidosis in 57 
which a lung biopsy showed extensive interstitial fibrosis and honeycombing without 58 
granulomatous inflammation. Most recently Xu and colleagues reviewed their experience with 9 59 
patients who underwent transplantation for sarcoidosis, dividing their patients into those with 60 
“active” and “fibrotic” disease based on the profusion of granulomatous inflammation in the 61 
explanted lungs.  Patients with “fibrotic” disease included two in whom no granulomas were 62 
present.  They concluded that late stage fibrotic disease, even when it lacks granulomatous 63 
features, is distinct from UIP but they did not include a control group12.   64 
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We compared lung explant findings in patients with a preoperative diagnosis of sarcoidosis to 65 
age and sex matched controls with UIP to characterize histopathologic features useful in 66 
distinguishing ESPS from UIP.  67 
Methods 68 
Thirteen patients with a clinical diagnosis of pulmonary sarcoidosis underwent lung 69 
transplantation (5 double-lung and 7 single-lung transplantations) between 1991 and 2012 at the 70 
University of Michigan. The diagnosis of sarcoidosis was based on criteria proposed in the joint 71 
statement on sarcoidosis by the American Thoracic Society, the European Respiratory Society, 72 
and the World Association of Sarcoidosis and Other Granulomatous Diseases (2). One patient 73 
was excluded because no slides were available for review. Controls were 10 age and sex matched 74 
lung transplant recipients with a postoperative diagnosis of UIP using previously published 75 
criteria 13-15. Patient demographic information, radiological findings and clinical diagnoses were 76 
obtained from the electronic medical record. This research was approved by the Institutional 77 
Review Board of the University of Michigan (project approval number HUM00063185) in 78 
accordance with the Institutional Committee for the Protection of Human Subjects. 79 
Hematoxylin and eosin (H&E)-stained sections were examined by three pulmonary pathologists 80 
(CZ, LAS and JLM) with documentation of the following features: extent/pattern of fibrosis; 81 
presence/quantity (per 10 high power fields) of fibroblast foci and granulomas; distribution and 82 
morphology of granulomas; presence of granulomas in hilar/mediastinal lymph nodes; 83 
presence/extent of honeycomb change. Extent of fibrosis and honeycomb change was scored as 84 
follows: 1=1-25%; 2=26-50%; 3=51-75%; 4=76-100% of lung parenchyma. Special stains 85 
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(Gomori methenamine silver and Ziehl-Neelsen) for fungi and acid-fast bacilli were performed 86 
on selected sections. 87 
A two-tailed Student t test was used to evaluate potential differences in continuous variables 88 
between different subgroups. A two-sided chi-square test was used to test potential differences in 89 
categorical variables of interest between different subgroups. Differences between groups were 90 
considered statistically significant if the p value was <0.05. 91 
Results 92 
Twelve explanted lungs from patients with a pre-transplant diagnosis of ESPS were divided into 93 
three categories based on histological findings. Group 1 (patients #1-8): ESPS; group 2 (patients 94 
#9 and 10): diseases other than ESPS; group 3 (patients # 11 and 12): overlapping features of 95 
sarcoidosis and other diseases. Clinical information for all groups is summarized in Tables 1 and 96 
2. 97 
The control group comprised 10 lung transplant recipients with a pathologic diagnosis of UIP. 98 
The underlying clinical condition was IPF in nine, including six men, with a mean age of 54.1 99 
years (range 40 – 62 years).   A 36-year-old woman with UIP had systemic lupus erythematosus 100 
(SLE).  101 
Group 1: ESPS (n = 8). 102 
Eight (66.7%) patients with a pre-transplant diagnosis of sarcoidosis had histologic findings 103 
consistent with previously reported features of ESPS. Patients included three (37.5%) women 104 
and ranged from 36 to 58 years of age (mean 45.9 years ± 8.2 years).  A diagnosis of sarcoidosis 105 
had been established 4 to 26 years prior to transplant (mean 14.1 years ± 8.3 years; median 11 106 
  7
years). A tissue diagnosis was made in six patients while clinical- radiologic findings led to a 107 
diagnosis of sarcoidosis in two (Table 1). Radiologic changes were consistent with sarcoidosis in 108 
all eight patients. Pulmonary function tests revealed severe to very severe obstructive ventilatory 109 
defects in four patients, a moderately severe to severe restrictive defect in three, and a combined 110 
restrictive and obstructive defect in one. Six patients had pulmonary hypertension defined as a 111 
mean pulmonary artery pressure (mPAP) > 25 mmHg based on right heart catheterization. 112 
Histologic findings are summarized in Table 3.  Non-necrotizing granulomas were present in the 113 
lung sections from all 8 cases (figure 1A). The granulomas were well formed with peripheral 114 
concentric fibrosis. Granulomas were distributed in a lymphangitic pattern, involving visceral 115 
pleura and subpleural parenchyma, bronchovascular bundles, and interlobular septa. Granulomas 116 
were identified in hilar and/or mediastinal lymph nodes in all 6 patients in whom lymph nodes 117 
were sampled. No granulomas were present in any of the control cases.  118 
Patchy fibrosis was identified in all cases of ESPS. The distribution of fibrosis followed a 119 
lymphangitic pattern, focally associated with non-necrotizing granulomas (figure 1B). In 120 
contrast, the patchy fibrosis in the control group was randomly distributed and was not 121 
associated with granulomatous inflammation (figure 1C). The fibrosis in ESPS had an average 122 
score of 2.1  1.0 compared to 3.5 ± 0.7 in UIP (p < 0.001). 123 
Focal honeycomb change was present in 3 of 8 (38%) ESPS cases. The extent of honeycomb 124 
change in ESPS cases ranged from 1% to 20% of lung parenchyma, with a consistent score of 1. 125 
In contrast, honeycomb change was present in all 10 control UIP cases, involving 5% to 60% of 126 
lung parenchyma, with an average score of 1.7  0.8. The prevalence of honeycomb change in 127 
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ESPS was significantly lower compared to UIP (37.5% vs 100%, p = 0.012); however, the 128 
difference in the extent of honeycomb change did not reach statistical significance (p = 0.061). 129 
Fibroblast foci were identified in 4 of 8 ESPS cases and 10 of 10 UIP cases (50% vs 100%, p = 130 
0.048). The average number of fibroblast foci in ESPS cases was 2.0  1.4/10HPF (range 1 to 131 
4/10HPF) compared to 7.0  3.5 in UIP (p = 0.002). 132 
Group 2: diseases other than sarcoidosis (n = 2) 133 
Two patients with a clinical diagnosis of pulmonary sarcoidosis had histological findings typical 134 
of diseases other than ESPS in their explanted lungs. 135 
Patient 9 was a 59-year-old Caucasian female who was diagnosed with sarcoidosis by 136 
mediastinal lymph node biopsy 4 years prior to lung transplantation. Chest CT scan showed 137 
extensive interlobular septal thickening in the periphery of both lungs, greater at the bases than at 138 
the apices, associated with traction bronchiectasis and honeycomb change. Pulmonary function 139 
testing demonstrated only isolated diffusion impairment. No pulmonary hypertension was 140 
present. Multiple sections prepared from her lung explant (figure 2A and 2B) showed a 141 
combination of findings characteristic of UIP including patchy fibrosis (50%), extensive 142 
honeycomb change (> 25%) and fibroblast foci (22/HPF). No granulomas were present in either 143 
the lung or hilar lymph nodes. 144 
Patient #10 was a 56-year old African American female whose diagnosis of sarcoidosis was 145 
established by open lung biopsy 22 years prior to transplantation. Those slides were not available 146 
for review.  The patient had a remote tobacco smoking history. Chest radiograph prior to 147 
transplantation demonstrated upper and mid-zone emphysema without hilar or mediastinal 148 
lymphadenopathy. Pulmonary function tests were consistent with a very severe obstructive 149 
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ventilatory defect. No pulmonary hypertension was present. Histological examination of the lung 150 
explant showed severe emphysematous changes, consistent with the clinical impression of 151 
chronic obstructive pulmonary disease (COPD). No honeycomb change or fibroblast foci were 152 
identified. No granulomas were identified in the lung or hilar lymph nodes. 153 
Group 3: overlap between ESPS and other diffuse lung diseases (n=2) 154 
Patient #11 was a 49-year-old African American female who was diagnosed with sarcoidosis by 155 
transbronchial biopsy 4 years prior to lung transplantation. Chest CT prior to transplantation 156 
showed “upper lobe reticulation and traction bronchiectasis with lower lobe predominant diffuse 157 
ground glass opacification” for which diagnostic considerations included both non-specific 158 
interstitial pneumonitis (NSIP) and sarcoidosis. Pulmonary function testing revealed a severe 159 
restrictive ventilatory defect with diffusion impairment.  Connective tissue disease serology was 160 
negative and her right heart catheterization revealed significant pulmonary hypertension (mPAP 161 
of 43 mmHg) with a normal right atrial pressure of 6 mmHg. An echocardiogram confirmed her 162 
pulmonary hypertension with right ventricular dilation. However, her pulmonary artery occlusion 163 
pressure was only 13 mmHg thereby eliminating left ventricular dysfunction as a cause of the 164 
pulmonary hypertension. The primary histopathologic finding from her explanted lung (Figure 165 
3C) was fibrosis with focal honeycomb change (score 1) and fibroblast foci (3/10 HPF) but with 166 
neither the patchwork fibrosis characteristic of UIP nor a lymphangitic distribution typical of 167 
ESPS. There were rare well-formed non-necrotizing granulomas distributed mainly along 168 
interlobular septa (Figure 3B) and in the hilar lymph nodes, similar to those seen in other ESPS 169 
cases (Figure 3A). Sections also showed marked chronic venous hypertension indicated by 170 
extensive capillary hemangiomatosis-like change expanding alveolar septa (Figure 3D). Her final 171 
pathologic diagnosis was pulmonary sarcoidosis and severe chronic venous hypertension.  172 
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Patient #12 was a 42-year-old African American female who was diagnosed with sarcoidosis on 173 
the basis of a liver biopsy 16 years prior to lung transplantation. She had been continuously 174 
treated with corticosteroids.  Her chief complaint was shortness of breath that had progressed 175 
over a period of several years. Chest CT showed extensive “honeycombing and cystic changes 176 
bilaterally with bilateral hilar lymphadenopathy and enlarged mediastinal lymph nodes.” 177 
Pulmonary physiology was consistent with severe restrictive lung disease and diffusion 178 
impairment. No pulmonary hypertension was present. Sections from her lung explant showed 179 
extensive fibrosis distributed in a random pattern (Figure 4C), with honeycomb change (score 1) 180 
and frequent fibroblast foci (5/10HPF), consistent with UIP. In addition, there were also well-181 
formed non-necrotizing granulomas in a lymphangitic distribution (Figure 4B), which were also 182 
present in the hilar lymph nodes (Figure 4A). Special stains of GMS and AFB were negative for 183 
microorganisms. Pathologic diagnosis was combined pulmonary sarcoidosis and UIP. 184 
Discussion 185 
A definite histopathologic diagnosis of ESPS was established in two thirds of our patients with a 186 
pre-transplant diagnosis of sarcoidosis.  The remaining patients were equally split between those 187 
with  an alternative diagnosis and those in whom sarcoidosis was combined with another diffuse 188 
lung disease. 189 
The histologic findings in ESPS are distinctly different from end stage UIP (Table 4).  The 190 
features most helpful in separating ESPS from UIP are the distribution of fibrosis and the 191 
presence or absence of granulomatous inflammation. Fibrosis in ESPS is distributed in a unique 192 
lymphangitic pattern that follows the distribution of the granulomas. In contrast, random and 193 
subpleural fibrosis and absence of granulomas are consistent features of UIP. The fibrosis in both 194 
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conditions can be associated with smooth muscle hyperplasia and scarring. The degree of 195 
architectural distortion in the forms of scarring and honeycomb change was generally milder in 196 
ESPS.  197 
Granulomatous inflammation is a consistent finding in the lungs of patients with ESPS, and was 198 
seen in all of our patients who had other supportive clinical, radiological and histolopathologic 199 
findings.  Others have suggested that granulomatous inflammation in ESPS may be obliterated 200 
by concentric fibrosis, a finding not seen in our patients16. It is conceivable that previously 201 
reported examples of ESPS without granulomatous inflammation may have represented patients 202 
with previous histories of sarcoidosis who, like some of ours, developed other fibrotic 203 
conditions.   Caution should be exercised in using lung granulomas as the defining pathologic 204 
feature of sarcoidosis because certain infections occurring in patients with other underlying 205 
diffuse lung diseases may also cause non-necrotizing sarcoid-like granulomas. For example, UIP 206 
complicated by MAC infections may mimic the histologic findings previously attributed to ESPS 207 
although the granulomas are more likely to be situated within air spaces rather than the fibrotic 208 
interstitium. Another histologic clue more commonly seen in infection than sarcoidosis is 209 
associated organizing pneumonia (8). Non-necrotizing granuloma in the hilar or mediastinal 210 
lymph nodes is another feature that consistently differentiated ESPS from UIP in our study.  211 
Fibroblast foci and honeycomb change are two features that are not specific, but when extensive, 212 
can be helpful in differentiating UIP from ESPS. In our current study, fibroblast foci were 213 
identified in 4 of 8 ESPS cases; however, they were quantitatively scarce. Honeycomb changes 214 
were present in 3 of 8 ESPS cases, but none of these changes were extensive in contrast to the 215 
extensive involvement characteristic of end stage UIP. 216 
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Our findings suggest that a subset of patients with an established diagnosis of sarcoidosis 217 
develop other diffuse lung diseases resulting in end stage pulmonary fibrosis. A reasonable 218 
explanation for the two patients in our series whose explanted lungs showed no histopathologic 219 
evidences of sarcoidosis is that their pulmonary sarcoidosis resolved prior to transplantation 220 
given that spontaneous remissions occur in nearly two thirds of patients5.  Alternatively, these 221 
patients may have been misdiagnosed with pulmonary sarcoidosis. Histopathologic examination 222 
of a mediastinal lymph node in case #9 and lung tissue in case #10 revealed non-caseating 223 
granulomas. Neither patient had evidence of extra-thoracic disease. Both Mukhopadhyay17 and 224 
Nazarullah18 have demonstrated that such granulomas have only about a 21-27% chance of 225 
representing sarcoidosis. We believe that both of these patients developed other forms of 226 
progressive diffuse fibrotic lung disease for which transplantation was performed.    227 
Although both sarcoidosis and IPF are relatively rare diseases, cases of combined sarcoidosis and 228 
IPF have been reported. Tachibana et al19 reported a patient who died of acute respiratory failure 229 
3 years after the diagnosis of sarcoidosis. The initial diagnosis was based on a mediastinoscopic 230 
biopsy of the mediastinal lymph nodes showing numerous noncaseating epithelioid granulomas. 231 
At autopsy, the lungs showed UIP with superimposed diffuse alveolar damage (DAD). It was 232 
concluded that the patient suffered from sarcoidosis and IPF during the observation period, and 233 
subsequently succumbed to an acute exacerbation of IPF. Nobata et al20 also described a case of 234 
pulmonary sarcoidosis with UIP distributed predominantly in the lower lung fields. In our 235 
current study, 2 of 12 patients who carried a diagnosis of sarcoidosis demonstrated histologic 236 
features of UIP in the explanted lungs, with or without concurrent features of pulmonary 237 
sarcoidosis. 238 
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In summary, ESPS has characteristic histopathologic features that distinguish it from other end 239 
stage lung diseases such as UIP. Recognizing these features may be helpful in identifying 240 
coexisting UIP in open lung biopsies of patients with known sarcoidosis. This may be of clinical 241 
significance since patients with sarcoidosis listed for lung transplantation have significantly 242 
longer wait times for an allograft than do patients with IPF21. 243 
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Table 1. Clinical and radiological information of all cases in the study group. 1 
Patient 
# Gender Ethnicity Age 
Interval 
from Dx to 
Txplt (years) 
Pre-txplt biopsy 
performed 
Extra-thoracic 
sarcoid (Y/N) 
Radiology 
technique consistent with ESPS* 
1 Male Caucasian 48 23 Yes (neck LN) Y HRCT ++ 
2 Female African American 39 8 No N CXR ++ 
3 Male Hispanic 42 8 Yes (open lung) N HRCT ++ 
4 Male Caucasian 40 4 Yes (open lung) N CXR ++ 
5 Female African American 48 22 No N CXR 0 
6 Male Caucasian 58 13 Yes (open lung) N CXR ++ 
7 Male African American 56 26 Yes (TBBX) N HRCT ++ 
8 Female African American 36 9 Yes (hilar LN) N CXR ++ 
9 Female Caucasian 59 4 Yes (mediastinal LN) N CT - 
10 Female African American 56 22 Yes (open lung) N CXR - 
11 Female African American 49 4 Yes (TBBX) N CT + 
12 Female African American 42 16 Yes (liver) Y CT + 
CXR: Chest X-Ray; CT: Computed tomography; Dx: Diagnosis; ESPS: End stage pulmonary sarcoidosis; HRCT: High resolution CT 2 
scan; LN: Lymph node; TBBX: Transbronchial biopsy; Txplt: Transplantation. 3 
* responses: ++ highly consistent; + consistent; 0: possible; - unlikely. 4 
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 1 
Table 2. Pulmonary function test results of all patients. 2 
Patient # 
Pulmonary Function Tests PHTN* (Y/N) 
FVC 
(Liter/%) 
FEV1 
(Liter/%) FEV1/FVC TLC (%) RV (%) 
DLCO 
(%)  
1 2.89/59 0.79/22 0.27 86 157 52 Y 
2 1.7/51 1.33/51 0.78 n/a n/a 37 Y 
3 1.45/30 1.02/27 0.70 38 n/a 44 Y 
4 2.34/48 0.77/21 0.33 108 240 n/a N 
5 1.84/57 0.99/40 0.54 n/a n/a n/a Y 
6 1.35/30 1.15/36 0.85 57 113 12 Y 
7 1.52/36 0.47/15 0.31 96 215 24 Y 
8 1.1/28 0.96/31 0.87 43 68 18 N 
9 2.77/118 2.21/129 0.80 101 88 28 N 
10 0.89/29 0.27/12 0.31 n/a n/a n/a N 
11 1.2/41 1.07/47 0.89 n/a n/a 29 Y 
12 1.36/35 1.08/36 0.79 36 n/a 33 N 
DLCO: Diffusion capacity to carbon monoxide; FEV1: Forced expiratory volume; FVC: Forced vital capacity; n/a: not available; 3 
PHTN: Pulmonary hypertension; RV: Residual volume; TLV: Total lung capacity. 4 
* PHTN was defined as mean pulmonary arterial pressure (mPAP) > 25 mmHg. 5 
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Table 3: Summary of histological findings of all cases in the study group. 1 
 
Case
# 
 
Fibrosis 
 
Fibroblast foci 
Architectural distortion  
Granulomas HCC scarring 
distrib-
ution 
extent 
(score) 
present 
(Y/N) 
extent 
(#/10HPF) 
present 
(Y/N) 
extent 
(score) 
present 
(Y/N) 
present 
(Y/N) 
extent 
(#/10HPF) 
distribution morphology present in 
LN (Y/N) 
1 patchy 4 N N/A N N/A Y Y 38 lymphangitic well-formed Y 
2 patchy 2 Y 4 Y 1 Y Y 22 lymphangitic well-formed N/A 
3 patchy 1 N N/A Y 1 N Y 13 lymphangitic well-formed Y 
4 patchy 2 N N/A N N/A Y Y 45 lymphangitic well-formed Y 
5 patchy 2 Y 1 N N/A Y Y 3 lymphangitic well-formed N/A 
6 patchy 2 N N/A N N/A Y Y 11 lymphangitic well-formed Y 
7 patchy 1 Y 1 N N/A Y Y 3 lymphangitic well-formed Y 
8 patchy 3 Y 2 Y 1 Y Y 13 lymphangitic well-formed Y 
9 patchy 3 Y 22 Y 1 Y N N/A N/A N/A N 
10 N/A 0 N N/A N N/A N N N/A N/A N/A N 
11 diffuse 4 Y 3 Y 1 Y Y 2 lymphangitic well-formed Y 
12 patchy 4 Y 5 1 1 Y Y 6 lymphangitic well-formed Y 
HCC: Honeycomb change; HPF: high power field; LN: lymph node; N/A: Not applicable. 2 
  3 
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Table 4: Comparison of major pathologic features of the ESPS cases and the UIP cases. 1 
Pathology features ESPS UIP 
Distribution of fibrosis Lymphangitic distribution Randomly distributed 
Fibroblast foci Absent or rare Frequent 
Architectural distortion Absent or mild Extensive 
Granuloma in the lung Present, lymphangitic distribution Absent, unless complicated by infections 
Granuloma in lymph nodes Present Absent 
ESPS: end stage pulmonary sarcoidosis; UIP: usual interstitial pneumonia. 2 
 3 
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Figure Legends 
Figure 1: All ESPS cases demonstrated well-formed granulomas within lung parenchyma; 
granulomas were also present in hilar or mediastinal lymph nodes in all patients for whom lymph 
nodes were available (A; H&E, 200x). Patchy fibrosis was also identified in all cases of ESPS 
(B; H&E, 20x), and this fibrosis was distributed in a lymphangitic pattern. In contrast, patchy 
fibrosis in the control cases was distributed in a random pattern (C; H&E, 20x). 
Figure 2: Sections taken from patient 9’s explant showed characteristic findings of usual 
interstitial pneumonia (UIP), including patchy fibrosis, fibroblast foci (A; H&E, 100x), and 
honeycomb change (B; H&E, 40x). 
Figure 3: Sections taken from the explant from patient 11 showed rare well-formed granulomas 
both within hilar lymph nodes (A; H&E, 100x) and along interlobular septa (B; H&E, 100x). 
There was also focal honeycomb change present (C; H&E, 40x) without other changes of UIP 
such as patchwork fibrosis. These findings were complicated by marked chronic venous 
hypertension including extensive capillary hemangiomatosis-like change (D; H&E, 200x). 
Figure 4: Sections from the explant of patient 12 demonstrate well-formed granulomas within 
hilar lymph nodes (A; H&E, 100x) and within a lymphangitic distribution (B; H&E, 100x) in 
pulmonary parenchyma. However, changes of UIP were also present, including fibroblast foci 
(arrowhead; C; H&E, 40x), randomly distributed fibrosis, and honeycomb change.  
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